Published in Cancer Weekly, December 13th, 2005
"This phase I study was conducted to assess the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor tyrosine kinase inhibitor PKI166 in patients with advanced solid malignancies. Experimental PKI166 was first given once daily continuously and in the second part of the study once daily for 2 weeks every 4 weeks to establish the MTD," researchers in the Netherlands reported.
"Ten additional patients were studied at MTD to acquire additional safety information and characterize the effect of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.